撤稿声明：萨马哈等人。单剂量伊维菌素对无症状SARS-CoV-2感染受试者病毒及临床结局的影响：黎巴嫩的一项试点临床试验。2021年，，989。
Retraction: Samaha et al. Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon. 2021, , 989.
作者信息
Samaha Ali A, Mouawia Hussein, Fawaz Mirna, Hassan Hamad, Salami Ali, Bazzal Ali Al, Saab Hamid Bou, Al-Wakeel Mohamed, Alsaabi Ahmad, Chouman Mohamad, Moussawi Mahmoud Al, Ayoub Hassan, Raad Ali, Hajjeh Ola, Eid Ali H, Raad Houssam
机构信息
Faculty of Public Health, Lebanese University, Beirut, Lebanon.
Nursing Department, Faculty of Health Sciences, Beirut Arab University, Beirut, Mazraa 1105, Lebanon.
出版信息
Viruses. 2021 Oct 26;13(11):2154. doi: 10.3390/v13112154.
Abstract
The journal retracts the article, Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon [...].
摘要
该期刊撤回了文章《单剂量伊维菌素对无症状SARS-CoV-2感染受试者病毒及临床结局的影响：黎巴嫩的一项初步临床试验》[...]。
相似文献
1
Retraction: Samaha et al. Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon. 2021, , 989.撤稿声明：萨马哈等人。单剂量伊维菌素对无症状SARS-CoV-2感染受试者病毒及临床结局的影响：黎巴嫩的一项试点临床试验。2021年，，989。
Viruses. 2021 Oct 26;13(11):2154. doi: 10.3390/v13112154.
2
Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon.伊维菌素单剂量对无症状 SARS-CoV-2 感染受试者病毒和临床结局的影响：黎巴嫩的一项初步临床试验。
Viruses. 2021 May 26;13(6):989. doi: 10.3390/v13060989.
3
The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.SARS-CoV-2 依维莫司纳瓦拉-ISGlobal 试验（SAINT）评估依维莫司在症状出现后 48 小时内降低低危、非重症 COVID-19 患者 COVID-19 传播风险的潜力：一项随机对照试验方案的研究方案结构化总结。
Trials. 2020 Jun 8;21(1):498. doi: 10.1186/s13063-020-04421-z.
4
Ivermectin for preventing and treating COVID-19.伊维菌素预防和治疗 COVID-19。
Cochrane Database Syst Rev. 2022 Jun 21;6(6):CD015017. doi: 10.1002/14651858.CD015017.pub3.
5
Retraction of Clinical Trials about the SARS-CoV-2 Infection: An Unaddressed Problem and Its Possible Impact on Coronavirus Disease (COVID)-19 Treatment.撤回关于 SARS-CoV-2 感染的临床试验：一个未解决的问题及其对冠状病毒病 (COVID-19) 治疗的可能影响。
Int J Environ Res Public Health. 2023 Jan 19;20(3):1835. doi: 10.3390/ijerph20031835.
6
Ivermectin compared with placebo in the clinical course in Mexican patients with asymptomatic and mild COVID-19: a randomized clinical trial.伊维菌素与安慰剂在无症状和轻症 COVID-19 墨西哥患者中的临床病程比较：一项随机临床试验。
BMC Infect Dis. 2022 Dec 8;22(1):917. doi: 10.1186/s12879-022-07890-6.
7
Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.随机临床试验比较伊维菌素与安慰剂对秘鲁早期 COVID-19 患者鼻咽 PCR 转阴的疗效（SAINT-Peru）：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 9;22(1):262. doi: 10.1186/s13063-021-05236-2.
8
High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial.大剂量伊维菌素早期治疗 COVID-19（COVER 研究）：一项随机、双盲、多中心、II 期、剂量探索、概念验证临床试验。
Int J Antimicrob Agents. 2022 Feb;59(2):106516. doi: 10.1016/j.ijantimicag.2021.106516. Epub 2022 Jan 6.
9
Use of ivermectin in the treatment of Covid-19: A pilot trial.伊维菌素用于治疗新冠病毒病：一项试点试验。
Toxicol Rep. 2021;8:505-510. doi: 10.1016/j.toxrep.2021.03.003. Epub 2021 Mar 9.
10
Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial.单剂量口服伊维菌素治疗轻中度 COVID-19（RIVET-COV）：一项单中心随机、安慰剂对照试验。
J Infect Chemother. 2021 Dec;27(12):1743-1749. doi: 10.1016/j.jiac.2021.08.021. Epub 2021 Aug 25.
引用本文的文献
1
"They Only Silence the Truth": COVID-19 retractions and the politicization of science.“他们只是在掩盖真相”：新冠疫情相关论文撤稿与科学的政治化
Public Underst Sci. 2025 Apr;34(3):291-306. doi: 10.1177/09636625241290142. Epub 2024 Oct 30.
2
Consistency of covid-19 trial preprints with published reports and impact for decision making: retrospective review.新冠病毒19临床试验预印本与已发表报告的一致性及其对决策的影响：回顾性审查
BMJ Med. 2022 Oct 3;1(1):e000309. doi: 10.1136/bmjmed-2022-000309. eCollection 2022.
3
Retraction of Clinical Trials about the SARS-CoV-2 Infection: An Unaddressed Problem and Its Possible Impact on Coronavirus Disease (COVID)-19 Treatment.撤回关于 SARS-CoV-2 感染的临床试验：一个未解决的问题及其对冠状病毒病 (COVID-19) 治疗的可能影响。
Int J Environ Res Public Health. 2023 Jan 19;20(3):1835. doi: 10.3390/ijerph20031835.
4
A Clinical Update on SARS-CoV-2: Pathology and Development of Potential Inhibitors.新型冠状病毒（SARS-CoV-2）的临床进展：病理学及潜在抑制剂的研发
Curr Issues Mol Biol. 2023 Jan 4;45(1):400-433. doi: 10.3390/cimb45010028.
5
Ivermectin compared with placebo in the clinical course in Mexican patients with asymptomatic and mild COVID-19: a randomized clinical trial.伊维菌素与安慰剂在无症状和轻症 COVID-19 墨西哥患者中的临床病程比较：一项随机临床试验。
BMC Infect Dis. 2022 Dec 8;22(1):917. doi: 10.1186/s12879-022-07890-6.
6
Outpatient purchasing patterns of hydroxychloroquine and ivermectin in the USA and Canada during the COVID-19 pandemic: an interrupted time series analysis from 2016 to 2021.美国和加拿大 COVID-19 大流行期间羟氯喹和伊维菌素的门诊购买模式：2016 年至 2021 年的中断时间序列分析。
J Antimicrob Chemother. 2022 Dec 23;78(1):242-251. doi: 10.1093/jac/dkac382.
7
Repurposing Potential of the Antiparasitic Agent Ivermectin for the Treatment and/or Prophylaxis of COVID-19.抗寄生虫药物伊维菌素用于治疗和/或预防2019冠状病毒病的潜在新用途。
Pharmaceuticals (Basel). 2022 Aug 27;15(9):1068. doi: 10.3390/ph15091068.
8
Identifying and managing problematic trials: A research integrity assessment tool for randomized controlled trials in evidence synthesis.识别和管理有问题的试验：证据综合中随机对照试验的研究诚信评估工具。
Res Synth Methods. 2023 May;14(3):357-369. doi: 10.1002/jrsm.1599. Epub 2022 Sep 15.
9
A Randomized Controlled Trial of Combined Ivermectin and Zinc Sulfate versus Combined Hydroxychloroquine, Darunavir/Ritonavir, and Zinc Sulfate among Adult Patients with Asymptomatic or Mild Coronavirus-19 Infection.一项关于伊维菌素与硫酸锌联合用药对比羟氯喹、达芦那韦/利托那韦与硫酸锌联合用药治疗无症状或轻度新型冠状病毒19感染成年患者的随机对照试验。
J Glob Infect Dis. 2022 Jun 29;14(2):69-74. doi: 10.4103/jgid.jgid_281_21. eCollection 2022 Apr-Jun.
10
Is Ivermectin Effective in Treating COVID-19?伊维菌素对治疗新冠肺炎有效吗？
Front Pharmacol. 2022 Jun 21;13:858693. doi: 10.3389/fphar.2022.858693. eCollection 2022.
Zotero 插件